8-K: Clene Inc. Announces Positive Long-Term Results for CNM-Au8 in Multiple Sclerosis Trial

Clene Inc. released data from its VISIONARY-MS trial long-term extension, showing significant evidence of repair and remyelination in multiple sclerosis patients treated with CNM-Au8.

Summary

• Clene Inc. presented long-term extension results from its Phase 2 VISIONARY-MS trial at the 2024 American Academy of Neurology Annual Meeting.
• The study evaluated the effects of CNM-Au8, a non-immunomodulatory drug, on patients with multiple sclerosis.
• The results showed significant improvements in clinical, functional, and structural outcomes with daily oral dosing of CNM-Au8 30 mg for up to three years.
• Participants originally on CNM-Au8 showed continued improvement in vision, with some improving by up to 38 letters on a low-contrast eye chart.
• Participants who switched from placebo to CNM-Au8 also experienced significant vision improvements.
• Cognition and working memory improved by up to 29 points as measured by the Symbol Digit Modality Test.
• Physiological measures showed improvements in signal strength and speed along the visual pathway, indicating neuronal health and remyelination.
• MRI scans showed improvements in brain lesions and markers of remyelination with long-term CNM-Au8 treatment.
• The treatment was well-tolerated with no significant safety findings observed.

Sentiment

Score: 9

Explanation: The document presents very positive clinical trial results with significant improvements across multiple endpoints and no safety concerns, suggesting a high likelihood of future success for the drug.

Positives

• CNM-Au8 demonstrated significant improvements in vision, cognition, and physiological markers related to neuronal health and remyelination.
• The treatment was well-tolerated over a three-year period with no significant safety concerns.
• The study showed consistent improvements across multiple clinical and paraclinical endpoints.
• Both participants originally on CNM-Au8 and those who switched from placebo experienced benefits.
• The results support the potential of CNM-Au8 as a treatment for repair and remyelination in MS.

Risks

• The company's future success depends on the successful commercialization of its drug candidates.
• Clinical trials may fail to demonstrate safety and efficacy to the satisfaction of regulatory authorities.
• Changes in government regulation could impact the need for the company's drug candidates.
• The company has a limited operating history, which may make it difficult to evaluate its current business and predict its future performance.
• The company's ability to continue as a going concern requires that it obtain sufficient funding to finance its operations.

Future Outlook

The consistent improvements observed in the VISIONARY-MS trial provide a clear impetus for a definitive Phase 3 study of CNM-Au8.

Management Comments

• Dr. Barnett stated that the consistent improvements in multiple clinical and paraclinical endpoints over three years of adjunctive treatment with CNM-Au8 provide clear impetus for a definitive Phase 3 study.
• Dr. Greenberg noted that observing such a profound clinical benefit with corresponding improvements in physiologic measures utilizing a mechanism that does not target immune system modulation has never been demonstrated in prior multiple sclerosis trials.

Industry Context

The results are significant as they represent a non-immunomodulatory approach to treating MS, which is different from many current therapies that focus on modulating the immune system. This could offer a new treatment option for patients.

Comparison to Industry Standards

• Most current MS treatments focus on immunomodulation, while CNM-Au8 targets mitochondrial function and the NAD pathway, offering a novel approach.
• The observed improvements in remyelination and neuronal function are notable, as many existing treatments primarily aim to slow disease progression rather than repair damage.
• The long-term nature of the study, with data spanning up to three years, provides a more comprehensive view of the treatment's efficacy and safety compared to shorter trials.
• The results are particularly compelling as they show improvements in both clinical and paraclinical endpoints, suggesting a broad impact of the treatment.

Stakeholder Impact

• Shareholders may view the positive trial results favorably, potentially increasing the company's stock value.
• Patients with MS may have a new treatment option that could improve their quality of life.
• The company's employees may be motivated by the positive results and the potential for future success.
• The company's suppliers and partners may benefit from the increased demand for CNM-Au8.

Next Steps

• The company plans to move forward with a definitive Phase 3 study of CNM-Au8 based on the positive results from the VISIONARY-MS trial.

Key Dates

Keywords

CNM-Au8, Multiple Sclerosis, Remyelination, Neurodegenerative Diseases, VISIONARY-MS, Clinical Trial, Mitochondrial Health, Neurological Function, Biopharmaceutical, Treatment